FyoniBio GmbH

FyoniBio GmbH is a Berlin-based contract research and development organization serving the biopharmaceutical industry. The company offers a comprehensive suite of integrated services that span the drug development lifecycle, including cell line and bioprocess development, advanced analytical characterization, and clinical bioanalysis. Their technical capabilities include proprietary platform technologies such as the human GlycoExpress platform, as well as CHOnamite and CHOFlow systems, which support the production of biologics. By centralizing these specialized services under one roof, FyoniBio aims to streamline the development process, reduce handover inefficiencies, and minimize communication gaps for their clients.

Formed as a spin-out from the immuno-oncology company Glycotope in 2022, FyoniBio leverages extensive experience in glycobiology and bioprocessing to support partners in navigating preclinical and clinical stages. They provide GCLP-compliant clinical bioanalysis and develop tailored assays for pharmacokinetics (PK), pharmacodynamics (PD), anti-drug antibodies (ADA), and biomarkers. Their services are designed to assist both small and large biotherapeutic molecules, ensuring compliance with international regulatory standards such as FDA and EMA guidelines. The company maintains an ISO 9001:2015 certification, reflecting their commitment to rigorous quality management and scientific reliability in supporting diverse biopharmaceutical development programs.